Can less chemo keep bladder cancer in check? new trial investigates
NCT ID NCT07183319
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether people with advanced bladder cancer can switch to a milder treatment after an initial strong combination therapy. Participants first receive two drugs (pembrolizumab and enfortumab vedotin) for 24 weeks. If their cancer is controlled, they then receive only pembrolizumab. The goal is to see if this de-escalation keeps the cancer from growing while reducing side effects. About 30 adults with metastatic urothelial carcinoma are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab and Enfortumab Vedotin
What this could lead to
If successful, this could show that some patients with metastatic bladder cancer can safely reduce their treatment intensity without losing disease control.
What could go wrong
This is a small, early-phase trial with only 30 participants. The cancer may progress during the de-escalation phase, and side effects from the drugs remain possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
OU Health Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73117, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••